Enliven Therapeutics, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.42 | — | — | Miss |
| 2026-05-13 | $-0.44 | — | — | Miss |
| Q12026 FY2026 | $-0.44 | $-0.38 | +13.6% | Beat |
| 2026-03-12 | $-0.42 | — | — | Miss |
Back to ELVN overview · ELVN holders · ELVN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.